{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T11:31:27Z","timestamp":1768735887669,"version":"3.49.0"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T00:00:00Z","timestamp":1701648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T00:00:00Z","timestamp":1701648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Biochem Biophys"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s12013-023-01200-w","type":"journal-article","created":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T12:02:28Z","timestamp":1701691348000},"page":"15-34","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Understanding CFTR Functionality: A Comprehensive Review of Tests and Modulator Therapy in Cystic Fibrosis"],"prefix":"10.1007","volume":"82","author":[{"given":"Shorya","family":"Thakur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Ankita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shubham","family":"Dash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rupali","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charanjit","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avijit","family":"Mazumder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gurvinder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,4]]},"reference":[{"issue":"10","key":"1200_CR1","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1016\/j.ymthe.2019.07.002","volume":"27","author":"O Villamizar","year":"2019","unstructured":"Villamizar, O., et al. (2019). Targeted activation of cystic fibrosis transmembrane conductance regulator. Molecular Therapy, 27(10), 1737\u20131748.","journal-title":"Molecular Therapy"},{"key":"1200_CR2","unstructured":"[cited 2023 22-08-2023]; Available from: https:\/\/www.yourgenome.org\/facts\/what-is-cystic-fibrosis\/."},{"issue":"1","key":"1200_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nrg3849","volume":"16","author":"GR Cutting","year":"2015","unstructured":"Cutting, G. R. (2015). Cystic fibrosis genetics: from molecular understanding to clinical application. Nature Reviews Genetics, 16(1), 45\u201356.","journal-title":"Nature Reviews Genetics"},{"issue":"6","key":"1200_CR4","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/nrm1949","volume":"7","author":"WB Guggino","year":"2006","unstructured":"Guggino, W. B., & Stanton, B. A. (2006). New insights into cystic fibrosis: molecular switches that regulate CFTR. Nature Reviews Molecular Cell Biology, 7(6), 426\u2013436.","journal-title":"Nature Reviews Molecular Cell Biology"},{"key":"1200_CR5","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","volume":"10","author":"M Lopes-Pacheco","year":"2019","unstructured":"Lopes-Pacheco, M. (2019). CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine. Frontiers in Pharmacology, 10, 1662.","journal-title":"Frontiers in Pharmacology"},{"issue":"8","key":"1200_CR6","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/S2213-2600(16)00023-0","volume":"4","author":"K De Boeck","year":"2016","unstructured":"De Boeck, K., & Amaral, M. D. (2016). Progress in therapies for cystic fibrosis. The Lancet Respiratory Medicine, 4(8), 662\u2013674.","journal-title":"The Lancet Respiratory Medicine"},{"key":"1200_CR7","doi-asserted-by":"crossref","unstructured":"Mall, M. A., & Hartl, D. (2014). CFTR: cystic fibrosis and beyond. European Respiratory Society.","DOI":"10.1183\/09031936.00228013"},{"key":"1200_CR8","unstructured":"Winikates, K. (2012). Cystic fibrosis transmembrane conductance regulator (CFTR) gene. In Embryo Project Encyclopedia. Arizona State University. School of Life Sciences. Center for Biology and Society. Embryo Project Encyclopedia."},{"issue":"19","key":"1200_CR9","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.2174\/13816128113199990321","volume":"19","author":"AS Verkman","year":"2013","unstructured":"Verkman, A. S., et al. (2013). CFTR inhibitors. Current Pharmaceutical Design, 19(19), 3529\u20133541.","journal-title":"Current Pharmaceutical Design"},{"key":"1200_CR10","unstructured":"[cited 2023 06-10-2023]; Available from: https:\/\/www.mayoclinic.org\/diseases-conditions\/cystic-fibrosis\/symptoms-causes\/syc-20353700."},{"issue":"2","key":"1200_CR11","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1128\/CMR.15.2.194-222.2002","volume":"15","author":"JB Lyczak","year":"2002","unstructured":"Lyczak, J. B., Cannon, C. L., & Pier, G. B. (2002). Lung infections associated with cystic fibrosis. Clinical Microbiology Reviews, 15(2), 194\u2013222.","journal-title":"Clinical Microbiology Reviews"},{"issue":"1","key":"1200_CR12","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1152\/physrev.1999.79.1.S3","volume":"79","author":"PM Quinton","year":"1999","unstructured":"Quinton, P. M. (1999). Physiological basis of cystic fibrosis: a historical perspective. Physiological Reviews, 79(1), S3\u2013S22.","journal-title":"Physiological Reviews"},{"key":"1200_CR13","first-page":"1214","volume":"10","author":"P Barbry","year":"2021","unstructured":"Barbry, P., Marcet, B. & Caballero, I. (2021). Where is the cystic fibrosis transmembrane conductance regulator? American Thoracic Society, 10, 1214\u20131216.","journal-title":"American Thoracic Society"},{"issue":"2","key":"1200_CR14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1258\/jrsm.2012.12s001","volume":"105","author":"J Hull","year":"2012","unstructured":"Hull, J. (2012). Cystic fibrosis transmembrane conductance regulator dysfunction and its treatment. Journal of the Royal Society of Medicine, 105(2), 2\u20138.","journal-title":"Journal of the Royal Society of Medicine"},{"key":"1200_CR15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3389\/fphar.2011.00067","volume":"2","author":"F Antigny","year":"2011","unstructured":"Antigny, F., et al. (2011). CFTR and Ca2+ signaling in cystic fibrosis. Frontiers in Pharmacology, 2, 67.","journal-title":"Frontiers in Pharmacology"},{"issue":"7083","key":"1200_CR16","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature04712","volume":"440","author":"DC Gadsby","year":"2006","unstructured":"Gadsby, D. C., Vergani, P., & Csan\u00e1dy, L. (2006). The ABC protein turned chloride channel whose failure causes cystic fibrosis. Nature, 440(7083), 477\u2013483.","journal-title":"Nature"},{"issue":"1","key":"1200_CR17","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cell.2017.02.024","volume":"169","author":"F Liu","year":"2017","unstructured":"Liu, F., et al. (2017). Molecular structure of the human CFTR ion channel. Cell, 169(1), 85\u201395.e8.","journal-title":"Cell"},{"issue":"50","key":"1200_CR18","doi-asserted-by":"publisher","first-page":"12757","DOI":"10.1073\/pnas.1815287115","volume":"115","author":"Z Zhang","year":"2018","unstructured":"Zhang, Z., Liu, F., & Chen, J. (2018). Molecular structure of the ATP-bound, phosphorylated human CFTR. Proceedings of the National Academy of Sciences, 115(50), 12757\u201312762.","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"1200_CR19","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3389\/fphar.2012.00201","volume":"3","author":"SJ Kim","year":"2012","unstructured":"Kim, S. J., & Skach, W. R. (2012). Mechanisms of CFTR folding at the endoplasmic reticulum. Frontiers in Pharmacology, 3, 201.","journal-title":"Frontiers in Pharmacology"},{"issue":"3","key":"1200_CR20","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/85429","volume":"7","author":"PM Quinton","year":"2001","unstructured":"Quinton, P. M. (2001). The neglected ion: HCO3\u2212. Nature Medicine, 7(3), 292\u2013293.","journal-title":"Nature Medicine"},{"issue":"6","key":"1200_CR21","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.molmed.2007.05.001","volume":"13","author":"RC Boucher","year":"2007","unstructured":"Boucher, R. C. (2007). Cystic fibrosis: a disease of vulnerability to airway surface dehydration. Trends in Molecular Medicine, 13(6), 231\u2013240.","journal-title":"Trends in Molecular Medicine"},{"key":"1200_CR22","doi-asserted-by":"publisher","first-page":"690247","DOI":"10.3389\/fphys.2021.690247","volume":"12","author":"A Della Sala","year":"2021","unstructured":"Della Sala, A., et al. (2021). Role of protein kinase A-mediated phosphorylation in CFTR channel activity regulation. Frontiers in Physiology, 12, 690247.","journal-title":"Frontiers in Physiology"},{"issue":"14","key":"1200_CR23","doi-asserted-by":"publisher","first-page":"4577","DOI":"10.1074\/jbc.RA119.008427","volume":"295","author":"J-H Chen","year":"2020","unstructured":"Chen, J.-H. (2020). Protein kinase A phosphorylation potentiates cystic fibrosis transmembrane conductance regulator gating by relieving autoinhibition on the stimulatory C terminus of the regulatory domain. Journal of Biological Chemistry, 295(14), 4577\u20134590.","journal-title":"Journal of Biological Chemistry"},{"issue":"2","key":"1200_CR24","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/j.jcf.2017.08.013","volume":"17","author":"H Li","year":"2018","unstructured":"Li, H., et al. (2018). Therapeutic approaches to CFTR dysfunction: from discovery to drug development. Journal of Cystic Fibrosis, 17(2), S14\u2013S21.","journal-title":"Journal of Cystic Fibrosis"},{"issue":"4","key":"1200_CR25","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1085\/jgp.201711946","volume":"150","author":"T-C Hwang","year":"2018","unstructured":"Hwang, T.-C., et al. (2018). Structural mechanisms of CFTR function and dysfunction. Journal of General Physiology, 150(4), 539\u2013570.","journal-title":"Journal of General Physiology"},{"key":"1200_CR26","unstructured":"[cited 2023 25-04-2023]; Available from: https:\/\/cftr2.org\/mutations_history."},{"issue":"9","key":"1200_CR27","first-page":"1053","volume":"199","author":"ET Zemanick","year":"2019","unstructured":"Zemanick, E.T. & Polineni, D. (2019). Unraveling the CFTR function\u2013phenotype connection for precision treatment in cystic fibrosis. American Thoracic Society, 199(9), 1053\u20131054.","journal-title":"American Thoracic Society"},{"key":"1200_CR28","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3389\/fphar.2012.00117","volume":"3","author":"M Wilschanski","year":"2012","unstructured":"Wilschanski, M. (2012). Class 1 CF mutations. Frontiers in Pharmacology, 3, 117.","journal-title":"Frontiers in Pharmacology"},{"issue":"4","key":"1200_CR29","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jcf.2013.12.003","volume":"13","author":"K De Boeck","year":"2014","unstructured":"De Boeck, K., et al. (2014). The relative frequency of CFTR mutation classes in European patients with cystic fibrosis. Journal of Cystic Fibrosis, 13(4), 403\u2013409.","journal-title":"Journal of Cystic Fibrosis"},{"issue":"1","key":"1200_CR30","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/nsmb882","volume":"12","author":"K Du","year":"2005","unstructured":"Du, K., Sharma, M., & Lukacs, G. L. (2005). The \u0394F508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR. Nature Structural & Molecular Biology, 12(1), 17\u201325.","journal-title":"Nature Structural & Molecular Biology"},{"issue":"29","key":"1200_CR31","doi-asserted-by":"publisher","first-page":"21592","DOI":"10.1016\/S0021-9258(20)80582-1","volume":"268","author":"G Lukacs","year":"1993","unstructured":"Lukacs, G., et al. (1993). The delta F508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane. Determination of functional half-lives on transfected cells. Journal of Biological Chemistry, 268(29), 21592\u201321598.","journal-title":"Journal of Biological Chemistry"},{"issue":"3","key":"1200_CR32","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jcf.2011.12.005","volume":"11","author":"H Yu","year":"2012","unstructured":"Yu, H., et al. (2012). Ivacaftor potentiation of multiple CFTR channels with gating mutations. Journal of Cystic Fibrosis, 11(3), 237\u2013245.","journal-title":"Journal of Cystic Fibrosis"},{"issue":"7","key":"1200_CR33","doi-asserted-by":"publisher","first-page":"e1004376","DOI":"10.1371\/journal.pgen.1004376","volume":"10","author":"J LaRusch","year":"2014","unstructured":"LaRusch, J., et al. (2014). Mechanisms of CFTR functional variants that impair regulated bicarbonate permeation and increase risk for pancreatitis but not for cystic fibrosis. PLoS Genetics, 10(7), e1004376.","journal-title":"PLoS Genetics"},{"issue":"5-6","key":"1200_CR34","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1159\/000257426","volume":"24","author":"AS Ramalho","year":"2009","unstructured":"Ramalho, A. S., et al. (2009). Deletion of CFTR translation start site reveals functional isoforms of the protein in CF patients. Cellular Physiology and Biochemistry, 24(5-6), 335\u2013346.","journal-title":"Cellular Physiology and Biochemistry"},{"key":"1200_CR35","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3389\/fphar.2019.00121","volume":"10","author":"I Pranke","year":"2019","unstructured":"Pranke, I., et al. (2019). Emerging therapeutic approaches for cystic fibrosis. From gene editing to personalized medicine. Frontiers in Pharmacology, 10, 121.","journal-title":"Frontiers in Pharmacology"},{"key":"1200_CR36","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jcf.2004.05.025","volume":"3","author":"C Norez","year":"2004","unstructured":"Norez, C., et al. (2004). Determination of CFTR chloride channel activity and pharmacology using radiotracer flux methods. Journal of Cystic Fibrosis, 3, 119\u2013121.","journal-title":"Journal of Cystic Fibrosis"},{"key":"1200_CR37","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1023\/A:1009766219974","volume":"19","author":"KJ Long","year":"1997","unstructured":"Long, K. J., & Walsh, K. B. (1997). Iodide efflux measurements with an iodide-selective electrode: a non-radioactive procedure for monitoring cellular chloride transport. Methods in Cell Science, 19, 207\u2013212.","journal-title":"Methods in Cell Science"},{"issue":"3","key":"1200_CR38","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.3390\/ijms23031437","volume":"23","author":"AS Ramalho","year":"2022","unstructured":"Ramalho, A. S., et al. (2022). Assays of CFTR function in vitro, ex vivo and in vivo. International Journal of Molecular Sciences, 23(3), 1437.","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"1200_CR39","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1006\/abio.1993.1143","volume":"210","author":"DE Orosz","year":"1993","unstructured":"Orosz, D. E., & Garlid, K. D. (1993). A sensitive new fluorescence assay for measuring proton transport across liposomal membranes. Analytical Biochemistry, 210(1), 7\u201315.","journal-title":"Analytical Biochemistry"},{"key":"1200_CR40","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jcf.2004.05.036","volume":"3","author":"F Munkonge","year":"2004","unstructured":"Munkonge, F., et al. (2004). Measurement of halide efflux from cultured and primary airway epithelial cells using fluorescence indicators. Journal of Cystic Fibrosis, 3, 171\u2013176.","journal-title":"Journal of Cystic Fibrosis"},{"key":"1200_CR41","doi-asserted-by":"crossref","unstructured":"Verkman, A. S., & Jayaraman, S. (2002). Fluorescent indicator methods to assay functional CFTR expression in cells. In Cystic fibrosis methods and protocols, Springer, 187\u2013196.","DOI":"10.1385\/1-59259-187-6:187"},{"issue":"8","key":"1200_CR42","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1089\/adt.2017.810","volume":"15","author":"E Smith","year":"2017","unstructured":"Smith, E., et al. (2017). A homogeneous cell-based halide-sensitive yellow fluorescence protein assay to identify modulators of the cystic fibrosis transmembrane conductance regulator ion channel. Assay and Drug Development Technologies, 15(8), 395\u2013406.","journal-title":"Assay and Drug Development Technologies"},{"issue":"1","key":"1200_CR43","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jcf.2018.05.004","volume":"18","author":"JP Clancy","year":"2019","unstructured":"Clancy, J. P., et al. (2019). CFTR modulator theratyping: current status, gaps and future directions. Journal of Cystic Fibrosis, 18(1), 22\u201334.","journal-title":"Journal of Cystic Fibrosis"},{"issue":"9","key":"1200_CR44","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1177\/1087057113488420","volume":"18","author":"R Maitra","year":"2013","unstructured":"Maitra, R., Sivashanmugam, P., & Warner, K. (2013). A rapid membrane potential assay to monitor CFTR function and inhibition. Journal of Biomolecular Screening, 18(9), 1132\u20131137.","journal-title":"Journal of Biomolecular Screening"},{"key":"1200_CR45","unstructured":"McManus, O. B., et al. (2012). Ion channel screening. In Assay Guidance Manual [Internet]."},{"key":"1200_CR46","doi-asserted-by":"crossref","unstructured":"Kodirov, S. A. (2023). Whole-cell patch-clamp recording and parameters. Biophysical Reviews 1\u201332.","DOI":"10.1007\/s12551-023-01055-8"},{"key":"1200_CR47","doi-asserted-by":"crossref","unstructured":"Cai, Z., et al. (2011). Application of high-resolution single-channel recording to functional studies of cystic fibrosis mutants. In Cystic fibrosis: diagnosis and protocols, Vol. I: Approaches to study and correct CFTR defects, Springer, 419\u2013441.","DOI":"10.1007\/978-1-61779-117-8_27"},{"key":"1200_CR48","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3389\/fphar.2017.00195","volume":"8","author":"A Billet","year":"2017","unstructured":"Billet, A., et al. (2017). Development of automated patch clamp technique to investigate CFTR chloride channel function. Frontiers in Pharmacology, 8, 195.","journal-title":"Frontiers in Pharmacology"},{"issue":"3","key":"1200_CR49","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1254\/fpj.123.211","volume":"123","author":"S-I Karaki","year":"2004","unstructured":"Karaki, S.-I., & Kuwahara, A. (2004). Electrophysiological measurement of transepithelial ion transport: short-circuit current (Ussing chamber) technique. Nihon Yakurigaku zasshi Folia Pharmacologica Japonica, 123(3), 211\u2013218.","journal-title":"Nihon Yakurigaku zasshi Folia Pharmacologica Japonica"},{"key":"1200_CR50","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jcf.2004.05.034","volume":"3","author":"HR De Jonge","year":"2004","unstructured":"De Jonge, H. R., et al. (2004). Ex vivo CF diagnosis by intestinal current measurements (ICM) in small aperture, circulating Ussing chambers. Journal of Cystic Fibrosis, 3, 159\u2013163.","journal-title":"Journal of Cystic Fibrosis"},{"issue":"4","key":"1200_CR51","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.jcf.2019.10.022","volume":"19","author":"KM de Winter\u2013de Groot","year":"2020","unstructured":"de Winter\u2013de Groot, K. M., et al. (2020). Forskolin-induced swelling of intestinal organoids correlates with disease severity in adults with cystic fibrosis and homozygous F508del mutations. Journal of Cystic Fibrosis, 19(4), 614\u2013619.","journal-title":"Journal of Cystic Fibrosis"},{"key":"1200_CR52","unstructured":"[cited 2023 19-08-2023]; Available from: https:\/\/www.huborganoids.nl\/forskolin-induced-swelling-fis-assay\/#:~:text=Activation%20of%20CFTR%20by%20forskolin%20leads%20to%20chloride,is%20determined%20as%20a%20measure%20for%20CFTR%20activity."},{"issue":"1","key":"1200_CR53","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/children10010004","volume":"10","author":"J Conti","year":"2022","unstructured":"Conti, J., Sorio, C., & Melotti, P. (2022). Organoid technology and its role for Theratyping applications in cystic fibrosis. Children, 10(1), 4.","journal-title":"Children"},{"issue":"2","key":"1200_CR54","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jcf.2022.01.008","volume":"21","author":"B Aalbers","year":"2022","unstructured":"Aalbers, B., et al. (2022). Forskolin induced swelling (FIS) assay in intestinal organoids to guide eligibility for compassionate use treatment in a CF patient with a rare genotype. Journal of Cystic Fibrosis, 21(2), 254\u2013257.","journal-title":"Journal of Cystic Fibrosis"},{"key":"1200_CR55","doi-asserted-by":"crossref","unstructured":"Sousa, M., et al. (2012). Measurements of CFTR-mediated Cl\u2212 secretion in human rectal biopsies constitute a robust biomarker for cystic fibrosis diagnosis and prognosis, e47708.","DOI":"10.1371\/journal.pone.0047708"},{"issue":"10","key":"1200_CR56","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1164\/rccm.201507-1271LE","volume":"192","author":"SY Graeber","year":"2015","unstructured":"Graeber, S. Y., et al. (2015). Intestinal current measurements detect activation of mutant CFTR in patients with cystic fibrosis with the G551D mutation treated with ivacaftor. American Journal of Respiratory and Critical Care Medicine, 192(10), 1252\u20131255.","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"5","key":"1200_CR57","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.jcf.2019.06.010","volume":"18","author":"MD Amaral","year":"2019","unstructured":"Amaral, M. D., et al. (2019). Theranostics by testing CFTR modulators in patient-derived materials: the current status and a proposal for subjects with rare CFTR mutations. Journal of Cystic Fibrosis, 18(5), 685\u2013692.","journal-title":"Journal of Cystic Fibrosis"},{"issue":"11","key":"1200_CR58","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1164\/rccm.201603-0459OC","volume":"194","author":"JM Collaco","year":"2016","unstructured":"Collaco, J. M., et al. (2016). Sources of variation in sweat chloride measurements in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine, 194(11), 1375\u20131382.","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"1200_CR59","unstructured":"[cited 2023 05-03-2023]; Available from: https:\/\/www.cff.org\/intro-cf\/sweat-test."},{"issue":"5","key":"1200_CR60","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.jcf.2015.01.005","volume":"14","author":"EF McKone","year":"2015","unstructured":"McKone, E. F., et al. (2015). Association of sweat chloride concentration at time of diagnosis and CFTR genotype with mortality and cystic fibrosis phenotype. Journal of Cystic Fibrosis, 14(5), 580\u2013586.","journal-title":"Journal of Cystic Fibrosis"},{"issue":"3","key":"1200_CR61","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jcf.2021.08.012","volume":"21","author":"A Reynaerts","year":"2022","unstructured":"Reynaerts, A., et al. (2022). Needle-free iontophoresis-driven \u03b2-adrenergic sweat rate test. Journal of Cystic Fibrosis, 21(3), 407\u2013415.","journal-title":"Journal of Cystic Fibrosis"},{"issue":"8","key":"1200_CR62","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1164\/rccm.201205-0922OC","volume":"186","author":"P Quinton","year":"2012","unstructured":"Quinton, P., et al. (2012). \u03b2-adrenergic sweat secretion as a diagnostic test for cystic fibrosis. American Journal of Respiratory and Critical Care Medicine, 186(8), 732\u2013739.","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"3","key":"1200_CR63","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.jcf.2021.10.005","volume":"21","author":"ST Pallenberg","year":"2022","unstructured":"Pallenberg, S. T., et al. (2022). CFTR modulation with elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis assessed by the \u03b2-adrenergic sweat rate assay. Journal of Cystic Fibrosis, 21(3), 442\u2013447.","journal-title":"Journal of Cystic Fibrosis"},{"issue":"1","key":"1200_CR64","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41390-019-0503-8","volume":"87","author":"DB Salinas","year":"2020","unstructured":"Salinas, D. B., et al. (2020). Image-based \u03b2-adrenergic sweat rate assay captures minimal cystic fibrosis transmembrane conductance regulator function. Pediatric Research, 87(1), 137\u2013145.","journal-title":"Pediatric Research"},{"issue":"1","key":"1200_CR65","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/ppul.26179","volume":"58","author":"M Zampoli","year":"2023","unstructured":"Zampoli, M., et al. (2023). \u03b2\u2010adrenergic sweat test in children with inconclusive cystic fibrosis diagnosis: Do we need new reference ranges? Pediatric Pulmonology, 58(1), 187\u2013196.","journal-title":"Pediatric Pulmonology"},{"key":"1200_CR66","doi-asserted-by":"crossref","unstructured":"Rowe, S. M., J. P. Clancy, J. P., & Wilschanski, M. (2011). Nasal potential difference measurements to assess CFTR ion channel activity. In Cystic fibrosis: diagnosis and protocols, Vol. I: Approaches to study and correct CFTR defects, Springer, 69\u201386.","DOI":"10.1007\/978-1-61779-117-8_6"},{"issue":"1","key":"1200_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/srep30780","volume":"6","author":"Z Su","year":"2016","unstructured":"Su, Z., et al. (2016). Systematic review and meta-analysis of nasal potential difference in hypoxia-induced lung injury. Scientific Reports, 6(1), 30780.","journal-title":"Scientific Reports"},{"issue":"6","key":"1200_CR68","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/MCP.0b013e32833f1d00","volume":"16","author":"PA Sloane","year":"2010","unstructured":"Sloane, P. A., & Rowe, S. M. (2010). Cystic fibrosis transmembrane conductance regulator protein repair as a therapeutic strategy in cystic fibrosis. Current Opinion in Pulmonary Medicine, 16(6), 591.","journal-title":"Current Opinion in Pulmonary Medicine"},{"key":"1200_CR69","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","volume":"10","author":"M Lopes-Pacheco","year":"2020","unstructured":"Lopes-Pacheco, M. (2020). CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine. Frontiers in Pharmacology, 10, 1662.","journal-title":"Frontiers in Pharmacology"},{"issue":"46","key":"1200_CR70","doi-asserted-by":"publisher","first-page":"35825","DOI":"10.1074\/jbc.M110.131623","volume":"285","author":"PH Thibodeau","year":"2010","unstructured":"Thibodeau, P. H., et al. (2010). The cystic fibrosis-causing mutation \u0394F508 affects multiple steps in cystic fibrosis transmembrane conductance regulator biogenesis. Journal of Biological Chemistry, 285(46), 35825\u201335835.","journal-title":"Journal of Biological Chemistry"},{"issue":"26","key":"1200_CR71","doi-asserted-by":"publisher","first-page":"19967","DOI":"10.1074\/jbc.M109.092684","volume":"285","author":"H Miki","year":"2010","unstructured":"Miki, H., et al. (2010). Potentiation of disease-associated cystic fibrosis transmembrane conductance regulator mutants by hydrolyzable ATP analogs. Journal of Biological Chemistry, 285(26), 19967\u201319975.","journal-title":"Journal of Biological Chemistry"},{"issue":"9","key":"1200_CR72","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.15252\/emmm.201607137","volume":"9","author":"SV Molinski","year":"2017","unstructured":"Molinski, S. V., et al. (2017). O rkambi\u00ae and amplifier co\u2010therapy improves function from a rare CFTR mutation in gene\u2010edited cells and patient tissue. EMBO Molecular Medicine, 9(9), 1224\u20131243.","journal-title":"EMBO Molecular Medicine"},{"key":"1200_CR73","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/BF03256658","volume":"2","author":"K Kunzelmann","year":"2003","unstructured":"Kunzelmann, K., & Mall, M. (2003). Pharmacotherapy of the ion transport defect in cystic fibrosis: role of purinergic receptor agonists and other potential therapeutics. American Journal of Respiratory Medicine, 2, 299\u2013309.","journal-title":"American Journal of Respiratory Medicine"},{"key":"1200_CR74","unstructured":"[cited 2023 08-03-2023]; Available from: https:\/\/go.drugbank.com\/drugs\/DB09280."},{"key":"1200_CR75","doi-asserted-by":"crossref","unstructured":"Wang, X., et al. (2018). Discovery of 4-[(2 R, 4 R)-4-({[1-(2, 2-Difluoro-1, 3-benzodioxol-5-yl) cyclopropyl] carbonyl} amino)-7-(difluoromethoxy)-3, 4-dihydro-2 H-chromen-2-yl] benzoic Acid (ABBV\/GLPG-2222), a potent cystic fibrosis transmembrane conductance regulator (CFTR) corrector for the treatment of cystic fibrosis. ACS Publications","DOI":"10.1021\/acs.jmedchem.7b01339"},{"issue":"11","key":"1200_CR76","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1021\/acsmedchemlett.9b00377","volume":"10","author":"MJ Scanio","year":"2019","unstructured":"Scanio, M. J., et al. (2019). Discovery of ABBV\/GLPG-3221, a potent corrector of CFTR for the treatment of cystic fibrosis. ACS Medicinal Chemistry Letters, 10(11), 1543\u20131548.","journal-title":"ACS Medicinal Chemistry Letters"},{"issue":"19","key":"1200_CR77","doi-asserted-by":"publisher","first-page":"11169","DOI":"10.1021\/acs.jmedchem.0c01050","volume":"63","author":"N Brindani","year":"2020","unstructured":"Brindani, N., et al. (2020). Identification, structure\u2013activity relationship, and biological characterization of 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles as a novel class of CFTR potentiators. Journal of Medicinal Chemistry, 63(19), 11169\u201311194.","journal-title":"Journal of Medicinal Chemistry"},{"issue":"1","key":"1200_CR78","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1021\/acs.jmedchem.0c01796","volume":"64","author":"EVDP Steven","year":"2021","unstructured":"Steven, E. V. D. P.(2021). Discovery of GLPG2451, a Novel Once Daily Potentiator for the Treatment of Cystic Fibrosis. Journal of Medicinal Chemistry, 64(1), 343\u2013353.","journal-title":"Journal of Medicinal Chemistry"},{"key":"1200_CR79","unstructured":"[cited 2023 25-05-2023]; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03540524#outcomemeasures."},{"key":"1200_CR80","unstructured":"[cited 2023 21-08-2023]; Available from: https:\/\/cysticfibrosisnewstoday.com\/news\/galapagos-announces-advancement-glpg2665-triple-combination-treatment-cystic-fibrosis-patients\/."},{"issue":"4","key":"1200_CR81","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/s11882-004-0077-2","volume":"4","author":"PD O\u2019Brien","year":"2004","unstructured":"O\u2019Brien, P. D., & Collum, L. M. (2004). Dry eye: diagnosis and current treatment strategies. Current Allergy and Asthma Reports, 4(4), 314\u2013319.","journal-title":"Current Allergy and Asthma Reports"},{"key":"1200_CR82","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s40135-013-0009-1","volume":"1","author":"M Uchino","year":"2013","unstructured":"Uchino, M., & Schaumberg, D. A. (2013). Dry eye disease: impact on quality of life and vision. Current Ophthalmology Reports, 1, 51\u201357.","journal-title":"Current Ophthalmology Reports"},{"issue":"3","key":"1200_CR83","doi-asserted-by":"publisher","first-page":"151","DOI":"10.4103\/0974-620X.169910","volume":"8","author":"S Shah","year":"2015","unstructured":"Shah, S., & Jani, H. (2015). Prevalence and associated factors of dry eye: our experience in patients above 40 years of age at a Tertiary Care Center. Oman Journal of Ophthalmology, 8(3), 151.","journal-title":"Oman Journal of Ophthalmology"},{"issue":"14","key":"1200_CR84","doi-asserted-by":"publisher","first-page":"DES192","DOI":"10.1167\/iovs.17-23651","volume":"59","author":"T Yamaguchi","year":"2018","unstructured":"Yamaguchi, T. (2018). Inflammatory response in dry eye. Investigative Ophthalmology & Visual Science, 59(14), DES192\u2013DES199.","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"2","key":"1200_CR85","first-page":"CD009729.","volume":"2","author":"AD Pucker","year":"2016","unstructured":"Pucker, A. D., Ng, S. M. & Nichols, J. J. (2016). Over the counter (OTC) artificial tear drops for dry eye syndrome. Cochrane Database of Systematic Reviews (2), 2(2), CD009729.","journal-title":"Cochrane Database of Systematic Reviews (2)"},{"issue":"10","key":"1200_CR86","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1136\/bjo.2005.070888","volume":"89","author":"S Tatlipinar","year":"2005","unstructured":"Tatlipinar, S., & Akpek, E. K. (2005). Topical ciclosporin in the treatment of ocular surface disorders. British Journal of Ophthalmology, 89(10), 1363\u20131367.","journal-title":"British Journal of Ophthalmology"},{"issue":"6","key":"1200_CR87","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1097\/ICO.0000000000000429","volume":"34","author":"D Wu","year":"2015","unstructured":"Wu, D., et al. (2015). Efficacy and safety of topical diquafosol ophthalmic solution for treatment of dry eye: a systematic review of randomized clinical trials. Cornea, 34(6), 644\u2013650.","journal-title":"Cornea"},{"issue":"6","key":"1200_CR88","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1076\/ceyr.21.6.918.6983","volume":"21","author":"R Itoh","year":"2000","unstructured":"Itoh, R., et al. (2000). Isolation and characterization of a Ca2+-activated chloride channel from human corneal epithelium. Current Eye Research, 21(6), 918\u2013925.","journal-title":"Current Eye Research"},{"issue":"3","key":"1200_CR89","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1076\/ceyr.24.3.182.8297","volume":"24","author":"HC Turner","year":"2002","unstructured":"Turner, H. C., Bernstein, A., & Candia, O. A. (2002). Presence of CFTR in the conjunctival epithelium. Current Eye Research, 24(3), 182\u2013187.","journal-title":"Current Eye Research"},{"issue":"7","key":"1200_CR90","doi-asserted-by":"publisher","first-page":"C767","DOI":"10.1152\/ajpcell.00195.2012","volume":"303","author":"D Yu","year":"2012","unstructured":"Yu, D., et al. (2012). Regional differences in rat conjunctival ion transport activities. American Journal of Physiology-Cell Physiology, 303(7), C767\u2013C780.","journal-title":"American Journal of Physiology-Cell Physiology"},{"issue":"5","key":"1200_CR91","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1096\/fj.201500180","volume":"30","author":"AM Flores","year":"2016","unstructured":"Flores, A. M., et al. (2016). Small-molecule CFTR activators increase tear secretion and prevent experimental dry eye disease. The FASEB Journal, 30(5), 1789.","journal-title":"The FASEB Journal"},{"issue":"9","key":"1200_CR92","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1097\/ICO.0b013e3181a16578","volume":"28","author":"ML Massingale","year":"2009","unstructured":"Massingale, M. L., et al. (2009). Analysis of inflammatory cytokines in the tears of dry eye patients. Cornea, 28(9), 1023\u20131027.","journal-title":"Cornea"},{"issue":"3","key":"1200_CR93","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jtos.2017.05.011","volume":"15","author":"AJ Bron","year":"2017","unstructured":"Bron, A. J., et al. (2017). Tfos dews ii pathophysiology report. The Ocular Surface, 15(3), 438\u2013510.","journal-title":"The Ocular Surface"},{"issue":"8","key":"1200_CR94","doi-asserted-by":"publisher","first-page":"3954","DOI":"10.3390\/ijms22083954","volume":"22","author":"HK Lee","year":"2021","unstructured":"Lee, H. K., et al. (2021). Isorhamnetin ameliorates dry eye disease via CFTR activation in mice. International Journal of Molecular Sciences, 22(8), 3954.","journal-title":"International Journal of Molecular Sciences"},{"issue":"9","key":"1200_CR95","doi-asserted-by":"publisher","first-page":"5206","DOI":"10.3390\/ijms23095206","volume":"23","author":"D Jeon","year":"2022","unstructured":"Jeon, D., et al. (2022). Novel CFTR activator Cact-3 ameliorates ocular surface dysfunctions in scopolamine-induced dry eye mice. International Journal of Molecular Sciences, 23(9), 5206.","journal-title":"International Journal of Molecular Sciences"},{"issue":"9370","key":"1200_CR96","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1016\/S0140-6736(03)13368-5","volume":"361","author":"EF McKone","year":"2003","unstructured":"McKone, E. F., et al. (2003). Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. The Lancet, 361(9370), 1671\u20131676.","journal-title":"The Lancet"},{"issue":"10","key":"1200_CR97","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1164\/rccm.200705-664OC","volume":"176","author":"PA Flume","year":"2007","unstructured":"Flume, P. A., et al. (2007). Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. American Journal of Respiratory and Critical Care Medicine, 176(10), 957\u2013969.","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"6","key":"1200_CR98","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.cell.2016.05.053","volume":"165","author":"MW Popp","year":"2016","unstructured":"Popp, M. W., & Maquat, L. E. (2016). Leveraging rules of nonsense-mediated mRNA decay for genome engineering and personalized medicine. Cell, 165(6), 1319\u20131322.","journal-title":"Cell"},{"issue":"12","key":"1200_CR99","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1097\/GIM.0b013e31818e55a2","volume":"10","author":"SM Moskowitz","year":"2008","unstructured":"Moskowitz, S. M., et al. (2008). Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders. Genetics in Medicine, 10(12), 851\u2013868.","journal-title":"Genetics in Medicine"},{"issue":"1","key":"1200_CR100","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/clpt.2012.183","volume":"93","author":"S Antunovic","year":"2013","unstructured":"Antunovic, S., Lukac, M., & Vujovic, D. (2013). Longitudinal cystic fibrosis care. Clinical Pharmacology & Therapeutics, 93(1), 86\u201397.","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"10059","key":"1200_CR101","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","volume":"388","author":"JS Elborn","year":"2016","unstructured":"Elborn, J. S. (2016). Cystic fibrosis. Lancet, 388(10059), 2519\u20132531.","journal-title":"Lancet"},{"issue":"11","key":"1200_CR102","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1164\/rccm.201301-0153OC","volume":"187","author":"JC Davies","year":"2013","unstructured":"Davies, J. C., et al. (2013). Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of Respiratory and Critical Care Medicine, 187(11), 1219\u20131225.","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"5","key":"1200_CR103","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nrd3723","volume":"11","author":"PB Davis","year":"2012","unstructured":"Davis, P. B., Yasothan, U., & Kirkpatrick, P. (2012). Ivacaftor. Nature Reviews Drug Discovery, 11(5), 349\u2013351.","journal-title":"Nature Reviews Drug Discovery"},{"issue":"46","key":"1200_CR104","doi-asserted-by":"publisher","first-page":"18843","DOI":"10.1073\/pnas.1105787108","volume":"108","author":"F Van Goor","year":"2011","unstructured":"Van Goor, F., et al. (2011). Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proceedings of the National Academy of Sciences, 108(46), 18843\u201318848.","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"3","key":"1200_CR105","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1056\/NEJMoa1409547","volume":"373","author":"CE Wainwright","year":"2015","unstructured":"Wainwright, C. E., et al. (2015). Lumacaftor\u2013ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. New England Journal of Medicine, 373(3), 220\u2013231.","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"1200_CR106","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1080\/17476348.2019.1602040","volume":"13","author":"PC Cheng","year":"2019","unstructured":"Cheng, P. C., Alexiou, S., & Rubenstein, R. C. (2019). Safety and efficacy of treatment with lumacaftor in combination with ivacaftor in younger patients with cystic fibrosis. Expert Review of Respiratory Medicine, 13(5), 417\u2013423.","journal-title":"Expert Review of Respiratory Medicine"},{"key":"1200_CR107","unstructured":"[cited 2023 20-08-2023]; Available from: https:\/\/go.drugbank.com\/drugs\/DB11712."},{"issue":"2","key":"1200_CR108","doi-asserted-by":"publisher","first-page":"00082.","DOI":"10.1183\/23120541.00082-2019","volume":"5","author":"JL Taylor-Cousar","year":"2019","unstructured":"Taylor-Cousar, J. L., et al. (2019). Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles. ERJ Open Research, 5(2), 00082.","journal-title":"ERJ Open Research"},{"issue":"18","key":"1200_CR109","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1007\/s40265-019-01233-7","volume":"79","author":"SM Hoy","year":"2019","unstructured":"Hoy, S. M. (2019). Elexacaftor\/ivacaftor\/tezacaftor: first approval. Drugs, 79(18), 2001\u20132007.","journal-title":"Drugs"}],"container-title":["Cell Biochemistry and Biophysics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12013-023-01200-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12013-023-01200-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12013-023-01200-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T07:28:14Z","timestamp":1708327694000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12013-023-01200-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,4]]},"references-count":109,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1200"],"URL":"https:\/\/doi.org\/10.1007\/s12013-023-01200-w","relation":{},"ISSN":["1085-9195","1559-0283"],"issn-type":[{"value":"1085-9195","type":"print"},{"value":"1559-0283","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,4]]},"assertion":[{"value":"11 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}